The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://sashayyzu385319.blog-a-story.com/20511737/glp-3-retatrutide-a-comparative-analysis